Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 29
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Novo Nordisk AS
NVO
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$38.95
0.66
1.71%
Ult. Agg.: Oct 29, 11:40 AM
Get Report
Panoramica
Notizie
Previsioni utili
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 6 giorni da adesso in mer nov 4th, prima dell'apertura del mercato
Conference call:
Conference call programmata per tra 7 giorni alle 7:00 AM
Clicca per vedere il webcast
Novo Nordisk Financials
Novo Nordisk (NVO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Eli Lilly Shares Trending On Retatrutide Win Ahead Of Earnings: What You Should Know
Eli Lilly shares rise 1.89% after hours following positive Phase 3 retatrutide diabetes trial results ahead of quarterly earnings.
Mohd Haider
PRO
At Novo Nordisk Capital Markets Day, Co CFO Says Reasonable To Expect That We Should Be Able To Grow The Company By Mid-Single Digits Compound Annual Growth Rate Toward 2030
https://edge.media-server.com/mmc/p/xdjeyf7u/
Benzinga Newsdesk
Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst
HIMS stock edges lower after mixed Q2 results. Needham analyst maintains Buy rating, raises PT to $42. Company's revenue up 38.2% YoY.
Priya Nigam
PRO
Novo Nordisk Q2 Adj. EPS $0.96 Beats $0.81 Estimate, Sales $12.209B Beat $11.350B Estimate
Novo Nordisk (NYSE:NVO) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.81 by 18.52 percent. This is a 5.49 percent increase over earnings of $0.91 per share from the same
Benzinga Newsdesk
Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks
Novo Nordisk raises 2026 guidance as Wegovy pill tops 5 million U.S. prescriptions, but stock falls despite higher GLP-1 sales expectations.
Vandana Singh
PRO
Novo Nordisk Expects Outlook FY Adjusted Revenue Growth -6 To 0%; Q2 Adj Sales Up 7% At CER; Adj Operating Profit Up 11% At CER; Raises 2026 Adj Sales, Operating Profit Outlook To 0% To -6% At Cer; Improved Outlook Is Driven By Increased Expectations For Glp-1 Product Sales
Novo Nordisk today announced adjusted sales and adjusted operating profit for the second quarter of 2026 and raised 2026 full-year adjusted sales and adjusted operating profit outlook at CER.
Benzinga Newsdesk
